Medullary thyroid cancer
Clinical trials for Medullary thyroid cancer explained in plain language.
Never miss a new study
Get alerted when new Medullary thyroid cancer trials appear
Sign up with your email to follow new studies for Medullary thyroid cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo therapy targets multiple cancers in new trial
Disease control Recruiting nowThis study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusio…
Matched conditions: MEDULLARY THYROID CANCER
Phase 1/2 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Custom mRNA vaccine takes on rare endocrine cancers
Disease control Recruiting nowThis early study tests a personalized mRNA vaccine (mRNA-0523-L001) for people with advanced endocrine tumors like adrenal cancer, medullary thyroid cancer, and pancreatic neuroendocrine tumors who have no standard treatment left. The vaccine is made to target unique mutations in…
Matched conditions: MEDULLARY THYROID CANCER
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New scan spots hidden thyroid tumors that resist standard treatment
Diagnosis Recruiting nowThis study tests whether a special PET scan using a radioactive tracer called 68Gallium-DOTATATE can better detect thyroid cancer that has spread and no longer responds to standard radioactive iodine therapy. About 54 adults with metastatic thyroid cancer will receive one injecti…
Matched conditions: MEDULLARY THYROID CANCER
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
New PET scan agent aims to better detect rare tumors
Diagnosis Recruiting nowThis study tests a new radioactive imaging agent called 68Ga-HA-DOTATATE to see if it can safely and accurately detect neuroendocrine tumors using PET/CT scans. About 600 people with known or suspected tumors will receive the agent and be followed for one year. The goal is to imp…
Matched conditions: MEDULLARY THYROID CANCER
Phase 2 • Sponsor: University of Alberta • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC